BoomRay Pharmaceutical Co., Ltd. is a clinical-stage biotech focusing on delivering innovative radioactive targeted drugs (RDC) for precise tumor diagnosis and treatment. Currently, BoomRay has multiple clinical-stage RTD products. The company has a management team led by overseas high-profile talents with rich backgrounds in the nuclear medicine industry and experience in drug design and translation. Relying on the technology platforms and basic research infrastructures of Peking University, and cooperating with many hospitals, BoomRay is committed to building itself into a first-class nuclear medicine company with original innovation and highly efficient industrial translation capabilities.